Abstract 20P
Background
Suicide among breast cancer (BC) patients is a significant concern. Previous research indicates increased psychological distress in these patients, but the effect of treatment types like neoadjuvant therapy on suicide risk is underexplored.
Methods
Utilizing data from the SEER 17 registries, this retrospective study included 435,070 female BC patients diagnosed between 2000 and 2010. Standardized Mortality Ratio (SMR) was calculated to compare observed suicide rates in our cohort to expected rates based on general population data. Suicide risks were analyzed using Poisson regression, and Mendelian randomization (MR) analysis was employed to examine the genetic correlations between BC and suicide.
Results
Peak suicide occurrences were noted at approximately 50.44 months post-diagnosis, with those receiving neoadjuvant therapy showing earlier suicide times at 45.13 months. SMR for patients aged 18-44 was lower in the neoadjuvant group [1.05 (95% CI: 0.45-2.06) compared to the adjuvant group [1.43 (95% CI: 1.00-1.98)]. Triple-negative BC patients undergoing adjuvant therapy exhibited the highest SMR [3.63 (95% CI: 1.33-7.90)]. Socioeconomic factors, including income and race, significantly influenced suicide risks, with middle-income white patients benefiting most from neoadjuvant therapy. Conversely, higher-income patients exhibited increased suicide risks. Mendelian Randomization (MR) analysis revealed no genetic correlation between BC and suicide, suggesting that external factors predominantly influence these outcomes.
Conclusions
Neoadjuvant therapy appears to reduce the risk of suicide in certain subgroups of BC patients. Our study underscores the importance of considering socioeconomic and demographic factors when assessing mental health impacts on breast cancer patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.